Effects of hydroxyurea in a population of Brazilian patients with sickle cell anemia

Detalhes bibliográficos
Autor(a) principal: Vicari, Perla [UNIFESP]
Data de Publicação: 2005
Outros Autores: Mello, Adriana Barretto de [UNIFESP], Figueiredo, Maria Stella [UNIFESP]
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UNIFESP
dARK ID: ark:/48912/0013000007zk8
Texto Completo: http://dx.doi.org/10.1002/ajh.20293
http://repositorio.unifesp.br/handle/11600/28158
Resumo: Fetal hemoglobin (HbF) inhibits the polymerization of sickle hemoglobin, modulating the clinical features of sickle cell anemia (SCA). Hydroxyurea (HU) therapy can increase the HbF level, although its production can be influenced by genetic determinants. Twenty-two Brazilian SCA patients were evaluated over 5 years before and after HU use. We analyzed (1) beta(S) haplotype; (2) patient characteristics; and (3) toxicity. No differences between age, sex, and HU response were observed. We found 40.9% of homozygous for Bantu haplotype, and, in contrasting to other trials, we observed HbF level increase in this group (3.84-9.08 g/dL, P = 0.003). Adverse effects were rare. Labyrinthitis was observed in 2 (9.10%) patients after HU use, although this complication had not been described before.
id UFSP_0dbc8a3ea1982401b288ea68993ec315
oai_identifier_str oai:repositorio.unifesp.br/:11600/28158
network_acronym_str UFSP
network_name_str Repositório Institucional da UNIFESP
repository_id_str 3465
spelling Effects of hydroxyurea in a population of Brazilian patients with sickle cell anemiafetal hemoglobinhydroxyureabeta(s) haplotypesickle cell anemiaFetal hemoglobin (HbF) inhibits the polymerization of sickle hemoglobin, modulating the clinical features of sickle cell anemia (SCA). Hydroxyurea (HU) therapy can increase the HbF level, although its production can be influenced by genetic determinants. Twenty-two Brazilian SCA patients were evaluated over 5 years before and after HU use. We analyzed (1) beta(S) haplotype; (2) patient characteristics; and (3) toxicity. No differences between age, sex, and HU response were observed. We found 40.9% of homozygous for Bantu haplotype, and, in contrasting to other trials, we observed HbF level increase in this group (3.84-9.08 g/dL, P = 0.003). Adverse effects were rare. Labyrinthitis was observed in 2 (9.10%) patients after HU use, although this complication had not been described before.Universidade Federal de São Paulo, UNIFESP, EPM, Disciplina Hematol & Hemoterapia, BR-04023000 São Paulo, BrazilUniversidade Federal de São Paulo, UNIFESP, EPM, Disciplina Hematol & Hemoterapia, BR-04023000 São Paulo, BrazilWeb of ScienceWiley-BlackwellUniversidade Federal de São Paulo (UNIFESP)Vicari, Perla [UNIFESP]Mello, Adriana Barretto de [UNIFESP]Figueiredo, Maria Stella [UNIFESP]2016-01-24T12:37:41Z2016-01-24T12:37:41Z2005-03-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion243-244http://dx.doi.org/10.1002/ajh.20293American Journal of Hematology. Hoboken: Wiley-liss, v. 78, n. 3, p. 243-244, 2005.10.1002/ajh.202930361-8609http://repositorio.unifesp.br/handle/11600/28158WOS:000227412900015ark:/48912/0013000007zk8engAmerican Journal of Hematologyinfo:eu-repo/semantics/openAccesshttp://olabout.wiley.com/WileyCDA/Section/id-406071.htmlreponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESP2022-09-27T10:00:03Zoai:repositorio.unifesp.br/:11600/28158Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestbiblioteca.csp@unifesp.bropendoar:34652024-12-11T20:03:59.312291Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false
dc.title.none.fl_str_mv Effects of hydroxyurea in a population of Brazilian patients with sickle cell anemia
title Effects of hydroxyurea in a population of Brazilian patients with sickle cell anemia
spellingShingle Effects of hydroxyurea in a population of Brazilian patients with sickle cell anemia
Vicari, Perla [UNIFESP]
fetal hemoglobin
hydroxyurea
beta(s) haplotype
sickle cell anemia
title_short Effects of hydroxyurea in a population of Brazilian patients with sickle cell anemia
title_full Effects of hydroxyurea in a population of Brazilian patients with sickle cell anemia
title_fullStr Effects of hydroxyurea in a population of Brazilian patients with sickle cell anemia
title_full_unstemmed Effects of hydroxyurea in a population of Brazilian patients with sickle cell anemia
title_sort Effects of hydroxyurea in a population of Brazilian patients with sickle cell anemia
author Vicari, Perla [UNIFESP]
author_facet Vicari, Perla [UNIFESP]
Mello, Adriana Barretto de [UNIFESP]
Figueiredo, Maria Stella [UNIFESP]
author_role author
author2 Mello, Adriana Barretto de [UNIFESP]
Figueiredo, Maria Stella [UNIFESP]
author2_role author
author
dc.contributor.none.fl_str_mv Universidade Federal de São Paulo (UNIFESP)
dc.contributor.author.fl_str_mv Vicari, Perla [UNIFESP]
Mello, Adriana Barretto de [UNIFESP]
Figueiredo, Maria Stella [UNIFESP]
dc.subject.por.fl_str_mv fetal hemoglobin
hydroxyurea
beta(s) haplotype
sickle cell anemia
topic fetal hemoglobin
hydroxyurea
beta(s) haplotype
sickle cell anemia
description Fetal hemoglobin (HbF) inhibits the polymerization of sickle hemoglobin, modulating the clinical features of sickle cell anemia (SCA). Hydroxyurea (HU) therapy can increase the HbF level, although its production can be influenced by genetic determinants. Twenty-two Brazilian SCA patients were evaluated over 5 years before and after HU use. We analyzed (1) beta(S) haplotype; (2) patient characteristics; and (3) toxicity. No differences between age, sex, and HU response were observed. We found 40.9% of homozygous for Bantu haplotype, and, in contrasting to other trials, we observed HbF level increase in this group (3.84-9.08 g/dL, P = 0.003). Adverse effects were rare. Labyrinthitis was observed in 2 (9.10%) patients after HU use, although this complication had not been described before.
publishDate 2005
dc.date.none.fl_str_mv 2005-03-01
2016-01-24T12:37:41Z
2016-01-24T12:37:41Z
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://dx.doi.org/10.1002/ajh.20293
American Journal of Hematology. Hoboken: Wiley-liss, v. 78, n. 3, p. 243-244, 2005.
10.1002/ajh.20293
0361-8609
http://repositorio.unifesp.br/handle/11600/28158
WOS:000227412900015
dc.identifier.dark.fl_str_mv ark:/48912/0013000007zk8
url http://dx.doi.org/10.1002/ajh.20293
http://repositorio.unifesp.br/handle/11600/28158
identifier_str_mv American Journal of Hematology. Hoboken: Wiley-liss, v. 78, n. 3, p. 243-244, 2005.
10.1002/ajh.20293
0361-8609
WOS:000227412900015
ark:/48912/0013000007zk8
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv American Journal of Hematology
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
http://olabout.wiley.com/WileyCDA/Section/id-406071.html
eu_rights_str_mv openAccess
rights_invalid_str_mv http://olabout.wiley.com/WileyCDA/Section/id-406071.html
dc.format.none.fl_str_mv 243-244
dc.publisher.none.fl_str_mv Wiley-Blackwell
publisher.none.fl_str_mv Wiley-Blackwell
dc.source.none.fl_str_mv reponame:Repositório Institucional da UNIFESP
instname:Universidade Federal de São Paulo (UNIFESP)
instacron:UNIFESP
instname_str Universidade Federal de São Paulo (UNIFESP)
instacron_str UNIFESP
institution UNIFESP
reponame_str Repositório Institucional da UNIFESP
collection Repositório Institucional da UNIFESP
repository.name.fl_str_mv Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)
repository.mail.fl_str_mv biblioteca.csp@unifesp.br
_version_ 1818602423100375040